Keratosis pilaris-like eruption secondary to nilotinib in a child
Marcos Oro-Ayude1, Marta Feito2, Lucía Quintana-Castanedo2
1Department of Dermatology, University Hospital of Pontevedra, Pontevedra (Galicia), Spain.
Abstract:
Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14-year-old patient being treated with nilotinib who developed a keratosis pilaris-like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism


